The first 60 days: Newly diagnosed multiple myeloma, transplant-ineligible
Most people with newly diagnosed myeloma are too old or frail for a stem cell transplant. Combining a CD38 antibody with lenalidomide and dexamethasone (MAIA) and, for the fitter, with bortezomib as well (IMROZ), now keeps the disease away for around five years in many and lengthens life. Below, week by week, is what OnCo's record of Newly diagnosed multiple myeloma, transplant-ineligible says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- Medical oncologistNamed in the standard of care for: Fit, transplant-ineligible, Intermediate fitness, Frail, Supportive care, all patients.
- Palliative and supportive care teamNamed in the standard of care for: Fit, transplant-ineligible, Intermediate fitness, Frail, Supportive care, all patients.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Daratumumab with lenalidomide and dexamethasone until progression (MAIA).
Isatuximab or daratumumab with bortezomib, lenalidomide and dexamethasone (IMROZ, CEPHEUS), continuing the antibody and lenalidomide until progression.
Daratumumab-Rd with reduced lenalidomide and dexamethasone, or lenalidomide-dexamethasone alone, with early dose reduction and steroid tapering.
Bisphosphonate or denosumab bone protection, antiviral and thrombosis prophylaxis, vaccination, renal protection and early management of neuropathy.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example IMWG frailty index, R-ISS and R2-ISS stage, FISH cytogenetics: del, t, t, gain 1q, Renal function and light chain burden, MRD by sequencing or flow cytometry), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Fit transplant-ineligible myeloma, Intermediate-fitness myeloma, Frail myeloma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Fit, transplant-ineligible
- For my situation (fit, transplant-ineligible), which of the standard options do you recommend and why?Guideline options include: Isatuximab or daratumumab with bortezomib, lenalidomide and dexamethasone (IMROZ, CEPHEUS), continuing the antibody and lenalidomide until progression.
- Am I a candidate for Isatuximab, Daratumumab, Bortezomib or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of IMROZ and CEPHEUS apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Intermediate fitness
- For my situation (intermediate fitness), which of the standard options do you recommend and why?Guideline options include: Daratumumab with lenalidomide and dexamethasone until progression (MAIA).
- Am I a candidate for Daratumumab, Lenalidomide, Dexamethasone, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Frail
- For my situation (frail), which of the standard options do you recommend and why?Guideline options include: Daratumumab-Rd with reduced lenalidomide and dexamethasone, or lenalidomide-dexamethasone alone, with early dose reduction and steroid tapering.
- Am I a candidate for Daratumumab, Lenalidomide, Dexamethasone, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Supportive care, all patients
- For my situation (supportive care, all patients), which of the standard options do you recommend and why?Guideline options include: Bisphosphonate or denosumab bone protection, antiviral and thrombosis prophylaxis, vaccination, renal protection and early management of neuropathy.
Any stage
- Are there clinical trials I could join, for example of Isatuximab, Daratumumab, Teclistamab, CARTITUDE-5?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Frail patients were excluded from the quadruplet trials and gain least from them”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Whether treatment can be fixed in duration or MRD-guided rather than continued until progression”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Newly diagnosed multiple myeloma, transplant-ineligible: the full pageMost people with newly diagnosed myeloma are too old or frail for a stem cell transplant. Combining a CD38 antibody with lenalidomide and dexamethasone (MAIA) and, for the fitter, with bortezomib as well (IMROZ), now keeps the disease away for around five years in many and lengthens life.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- VRd and Dara-VRd (myeloma induction regimens): The alphabet soup of myeloma treatment: V (bortezomib, Velcade), R (lenalidomide, Revlimid), d (dexamethasone), Dara (daratumumab), Isa (isatuximab), K (carfilzomib).
- MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶): MRD negativity means no detectable myeloma cell among 100,000 or a million marrow cells.
- R-ISS / R2-ISS staging: R-ISS is the myeloma staging system, combining blood markers with high-risk chromosome changes to predict outcome.
- Immunomodulatory drugs (IMiDs) and CELMoDs: Thalidomide and its descendants lenalidomide and pomalidomide, which hijack a cellular waste-disposal tag (cereblon) to destroy two proteins myeloma cells depend on, while also revving up T and NK cells.
- Proteasome inhibitor (bortezomib, carfilzomib, ixazomib): Drugs that block the cell's protein-recycling machine.
- Maintenance therapy: Ongoing, gentler treatment given after the main course has shrunk the cancer, to hold it in check for as long as possible rather than to shrink it further.
Every term links to the glossary.